Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy

Abstract Background Severe ventricular rhythm disturbances are the hallmark of arrhythmogenic cardiomyopathy (ACM), and are often explained by structural conduction abnormalities. However, comprehensive investigations of ACM cell electrical instability are lacking. This study aimed to elucidate earl...

Full description

Bibliographic Details
Main Authors: Adrien Moreau, Jean‐Baptiste Reisqs, Helene Delanoe‐Ayari, Marion Pierre, Alexandre Janin, Antoine Deliniere, Francis Bessière, Albano C. Meli, Azzouz Charrabi, Estele Lafont, Camille Valla, Delphine Bauer, Elodie Morel, Vincent Gache, Gilles Millat, Xavier Nissan, Adele Faucherre, Chris Jopling, Sylvain Richard, Alexandre Mejat, Philippe Chevalier
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Clinical and Translational Medicine
Subjects:
Online Access:https://doi.org/10.1002/ctm2.319
id doaj-c9664adcb3fe4088aa3cbb1ca8360b5b
record_format Article
spelling doaj-c9664adcb3fe4088aa3cbb1ca8360b5b2021-03-30T14:25:35ZengWileyClinical and Translational Medicine2001-13262021-03-01113n/an/a10.1002/ctm2.319Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapyAdrien Moreau0Jean‐Baptiste Reisqs1Helene Delanoe‐Ayari2Marion Pierre3Alexandre Janin4Antoine Deliniere5Francis Bessière6Albano C. Meli7Azzouz Charrabi8Estele Lafont9Camille Valla10Delphine Bauer11Elodie Morel12Vincent Gache13Gilles Millat14Xavier Nissan15Adele Faucherre16Chris Jopling17Sylvain Richard18Alexandre Mejat19Philippe Chevalier20PhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FrancePhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FranceInstitut lumière matière Claude Bernard University, Lyon 1 Villeurbanne FrancePhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceService de Rythmologie Hospices Civils de Lyon Lyon FranceService de Rythmologie Hospices Civils de Lyon Lyon FrancePhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FrancePhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceCECS I‐Stem Corbeil‐Essonnes FranceIGF, CNRS, INSERM Université de Montpellier Montpellier FranceIGF, CNRS, INSERM Université de Montpellier Montpellier FrancePhyMedExp INSERM U1046 CNRS UMR9214 Université de Montpellier Montpellier FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceNeuromyogene Institut Claude Bernard University, Lyon 1 Villeurbanne FranceAbstract Background Severe ventricular rhythm disturbances are the hallmark of arrhythmogenic cardiomyopathy (ACM), and are often explained by structural conduction abnormalities. However, comprehensive investigations of ACM cell electrical instability are lacking. This study aimed to elucidate early electrical myogenic signature of ACM. Methods We investigated a 41‐year‐old ACM patient with a missense mutation (c.394C>T) in the DSC2 gene, which encodes desmocollin 2. Pathogenicity of this variant was confirmed using a zebrafish DSC2 model system. Control and DSC2 patient‐derived pluripotent stem cells were reprogrammed and differentiated into cardiomyocytes (hiPSC‐CM) to examine the specific electromechanical phenotype and its modulation by antiarrhythmic drugs (AADs). Samples of the patient's heart and hiPSC‐CM were examined to identify molecular and cellular alterations. Results A shortened action potential duration was associated with reduced Ca2+ current density and increased K+ current density. This finding led to the elucidation of previously unknown abnormal repolarization dynamics in ACM patients. Moreover, the Ca2+ mobilised during transients was decreased, and the Ca2+ sparks frequency was increased. AAD testing revealed the following: (1) flecainide normalised Ca2+ transients and significantly decreased Ca2+ spark occurrence and (2) sotalol significantly lengthened the action potential and normalised the cells’ contractile properties. Conclusions Thorough analysis of hiPSC‐CM derived from the DSC2 patient revealed abnormal repolarization dynamics, prompting the discovery of a short QT interval in some ACM patients. Overall, these results confirm a myogenic origin of ACM electrical instability and provide a rationale for prescribing class 1 and 3 AADs in ACM patients with increased ventricular repolarization reserve.https://doi.org/10.1002/ctm2.319action potential durationarrhythmogenic cardiomyopathydesmocollinhiPSC‐CMQT duration
collection DOAJ
language English
format Article
sources DOAJ
author Adrien Moreau
Jean‐Baptiste Reisqs
Helene Delanoe‐Ayari
Marion Pierre
Alexandre Janin
Antoine Deliniere
Francis Bessière
Albano C. Meli
Azzouz Charrabi
Estele Lafont
Camille Valla
Delphine Bauer
Elodie Morel
Vincent Gache
Gilles Millat
Xavier Nissan
Adele Faucherre
Chris Jopling
Sylvain Richard
Alexandre Mejat
Philippe Chevalier
spellingShingle Adrien Moreau
Jean‐Baptiste Reisqs
Helene Delanoe‐Ayari
Marion Pierre
Alexandre Janin
Antoine Deliniere
Francis Bessière
Albano C. Meli
Azzouz Charrabi
Estele Lafont
Camille Valla
Delphine Bauer
Elodie Morel
Vincent Gache
Gilles Millat
Xavier Nissan
Adele Faucherre
Chris Jopling
Sylvain Richard
Alexandre Mejat
Philippe Chevalier
Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy
Clinical and Translational Medicine
action potential duration
arrhythmogenic cardiomyopathy
desmocollin
hiPSC‐CM
QT duration
author_facet Adrien Moreau
Jean‐Baptiste Reisqs
Helene Delanoe‐Ayari
Marion Pierre
Alexandre Janin
Antoine Deliniere
Francis Bessière
Albano C. Meli
Azzouz Charrabi
Estele Lafont
Camille Valla
Delphine Bauer
Elodie Morel
Vincent Gache
Gilles Millat
Xavier Nissan
Adele Faucherre
Chris Jopling
Sylvain Richard
Alexandre Mejat
Philippe Chevalier
author_sort Adrien Moreau
title Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy
title_short Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy
title_full Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy
title_fullStr Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy
title_full_unstemmed Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy
title_sort deciphering dsc2 arrhythmogenic cardiomyopathy electrical instability: from ion channels to ecg and tailored drug therapy
publisher Wiley
series Clinical and Translational Medicine
issn 2001-1326
publishDate 2021-03-01
description Abstract Background Severe ventricular rhythm disturbances are the hallmark of arrhythmogenic cardiomyopathy (ACM), and are often explained by structural conduction abnormalities. However, comprehensive investigations of ACM cell electrical instability are lacking. This study aimed to elucidate early electrical myogenic signature of ACM. Methods We investigated a 41‐year‐old ACM patient with a missense mutation (c.394C>T) in the DSC2 gene, which encodes desmocollin 2. Pathogenicity of this variant was confirmed using a zebrafish DSC2 model system. Control and DSC2 patient‐derived pluripotent stem cells were reprogrammed and differentiated into cardiomyocytes (hiPSC‐CM) to examine the specific electromechanical phenotype and its modulation by antiarrhythmic drugs (AADs). Samples of the patient's heart and hiPSC‐CM were examined to identify molecular and cellular alterations. Results A shortened action potential duration was associated with reduced Ca2+ current density and increased K+ current density. This finding led to the elucidation of previously unknown abnormal repolarization dynamics in ACM patients. Moreover, the Ca2+ mobilised during transients was decreased, and the Ca2+ sparks frequency was increased. AAD testing revealed the following: (1) flecainide normalised Ca2+ transients and significantly decreased Ca2+ spark occurrence and (2) sotalol significantly lengthened the action potential and normalised the cells’ contractile properties. Conclusions Thorough analysis of hiPSC‐CM derived from the DSC2 patient revealed abnormal repolarization dynamics, prompting the discovery of a short QT interval in some ACM patients. Overall, these results confirm a myogenic origin of ACM electrical instability and provide a rationale for prescribing class 1 and 3 AADs in ACM patients with increased ventricular repolarization reserve.
topic action potential duration
arrhythmogenic cardiomyopathy
desmocollin
hiPSC‐CM
QT duration
url https://doi.org/10.1002/ctm2.319
work_keys_str_mv AT adrienmoreau decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT jeanbaptistereisqs decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT helenedelanoeayari decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT marionpierre decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT alexandrejanin decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT antoinedeliniere decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT francisbessiere decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT albanocmeli decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT azzouzcharrabi decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT estelelafont decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT camillevalla decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT delphinebauer decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT elodiemorel decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT vincentgache decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT gillesmillat decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT xaviernissan decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT adelefaucherre decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT chrisjopling decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT sylvainrichard decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT alexandremejat decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
AT philippechevalier decipheringdsc2arrhythmogeniccardiomyopathyelectricalinstabilityfromionchannelstoecgandtailoreddrugtherapy
_version_ 1724180596338458624